Clinical Cases in Pharmacology Clinical Cases  ·  Urology Vol. I  ·  Endourology  ·  Fourteen Months on the Road, and a Stent Nobody Was Watching
Urology Vol. I, Case UroEndo-0009 — Endourology

Fourteen Months on the Road, and a Stent Nobody Was Watching

Alkalinizing the urine has real trial support for stopping new stones from forming. A dedicated trial says it doesn't touch stent encrustation at all — and the actual driver of his encrustation hasn't even been identified yet.

Abbreviations, terms, and other agents mentioned in this case DJ stent — double-J (ureteral) stent  ·  ESWL — extracorporeal shockwave lithotripsy
Presentation

Vernon A., a 51-year-old man, has driven long-haul freight routes for twenty-six years, sleeping in the cab more nights than not and routing his life around delivery windows that don't move for anyone's follow-up appointment. A double-J stent placed fourteen months ago after ureteroscopy for a ureteral stone was supposed to come out within six weeks; instead, three scheduled removal appointments came and went while Vernon was somewhere on I-80, and by the time a persistent dull ache finally got him into an urgent-care clinic near home, imaging showed a stent so heavily encrusted at both coils that it had become, functionally, a second stone.

The actual treatment for a stent this far gone is mechanical, not pharmacologic — a staged combination of shockwave lithotripsy and endoscopic removal, already scheduled for next week. The question in front of the team today is narrower: while Vernon waits, is there anything worth starting to slow further encrustation and reduce his infection risk in the interim? Oral alkalinizing citrate has genuine, well-established evidence for preventing new stone formation by raising urinary pH, and it's tempting to reach for the same drug here. But Ch'ng and colleagues randomized 115 stented patients to sodium citrate or none, specifically to test alkalinization against encrustation on an existing device rather than against stone formation, and found no significant effect on encrustation at all. The likelier driver of encrustation this severe is a urease-producing organism forming a crystalline bacterial biofilm directly on the stent surface, a distinct process alkalinization doesn't touch, and nobody has actually sent a urine culture to find out whether that's what's growing on Vernon's.

Vernon A. · 51 Awaiting mechanical removal
Stent history
DJ stent placed 14 months ago, 3 missed removal appointments (irregular work travel)
Imaging
Heavy encrustation, both coils; functions as a second calculus
Planned treatment
Staged ESWL + endoscopic removal, scheduled next week
Urine culture
Not yet obtained
Renal function
Creatinine 1.1, stable

Urology clinic, one week before staged removal

Urologist Opening

He's got a week to wait for the staged removal, and I don't love the idea of doing nothing pharmacologically in the meantime. Citrate has strong, repeated trial evidence for preventing new stone formation by raising urinary pH — I'd start it now.

Antimicrobial Stewardship Pharmacist Response

I'd stop and separate two different claims. Citrate's evidence is real for stone PREVENTION — the metabolic, supersaturation-driven process. Stent ENCRUSTATION specifically has been tested directly: Ch'ng's randomized trial gave 115 stented patients sodium citrate or nothing until stent removal and found no significant reduction in encrustation.

Those are two different indications wearing the same drug name. Extending citrate's stone-prevention evidence to an encrustation question it's already been tested against — and failed — isn't caution, it's treating a negative trial as if it doesn't count.

Clinical Pharmacologist Final

You're both reaching for a drug before we know what we're actually treating. Severe encrustation like this is most often driven by a urease-producing organism building a crystalline biofilm directly on the stent surface — a bacterial process citrate was never going to touch, negative trial or not. And it's worth noting the one oral agent that has beaten placebo on this endpoint went the other way pharmacologically: Torrecilla's multicentre trial of an L-methionine composition, which ACIDIFIES urine, cut global encrustation from 8.2% to 1%. Alkalinizing isn't a weak lever here. It may be the wrong direction.

Nobody has sent a culture. Given how long Vernon was lost to follow-up, we genuinely don't know whether this is an infected, urease-driven encrustation or something closer to sterile metabolic buildup. I'd get the culture today and let the result decide — if it grows a urease-producer, culture-directed suppressive antibiotics as a bridge to removal make real sense; if it's sterile, neither citrate nor empiric antibiotics is supported by anything specific to him.

Regimen selected
Urine Culture — Obtained First
Diagnostic · Result pending
Neither pharmacologic option is grounded in anything patient-specific until this result exists, given how long he was lost to follow-up.
Culture-Directed Antibiotic Suppression
Contingent · Pending culture result
Reasonable as a bridge to mechanical removal only if a urease-producing organism is confirmed; not started empirically.
Potassium Citrate — Ruled Out
Urinary Alkalinizing Agent · Not selected
Ch'ng et al.'s dedicated randomized trial of sodium citrate found no significant effect on stent encrustation specifically, with the conclusion framed for alkaline citrates generally — distinct from citrate's real, separate role in metabolic stone prevention.
Empiric Broad-Spectrum Antibiotics — Ruled Out
Considered, not adopted
No current infection symptoms, and starting empirically ahead of a culture result — with mechanical removal already a week away — was judged an unjustified stewardship cost.
Where this was left

Agreed: urine culture sent today, no pharmacologic therapy started pending the result. Potassium citrate was explicitly declined for this indication, with the Urologist's initial instinct corrected directly by the trial finding the Antimicrobial Stewardship Pharmacist named — a genuine revision, not a smoothed-over disagreement.

What happens if the culture grows a urease-producing organism — whether to start suppressive antibiotics for the week before removal — was left open, contingent on a result nobody has yet. Vernon was also given a direct phone line to reschedule around his route, rather than a standard mailed appointment reminder, given what produced this situation in the first place.

Educational content only — a composite teaching case, not a real patient encounter or a substitute for clinical guidance. About These Cases →